SAB Biotherapeutics, Inc. (SABS)
Develops antibody treatments for autoimmune diseases and infections using genetically modified animals.
$3.45+0.00%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago+54.7%
The outlook
SABS is trading below both its 50- and 200-day moving averages, placing it in the lower half of its 52-week range. Analyst coverage shows an average price target roughly 224% above the current price, though the overall sentiment leans bearish. The stock remains flat today with modest analyst support.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range48% of the way from its 52-week low to high
Price targetAvg target +224% vs current price
Analyst price target
~12-month · 11 analysts$11.18average target+224.1% vs now
Now $3.45
Low $6.00High $16.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$263.8M
52-wk high
$5.15
52-wk low
$1.85
50-day avg
$3.67
200-day avg
$3.70
Trailing P/E
—